Share

September 2018; 5 (5) ArticleOpen Access

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI

Kianush Karimian-Jazi, Brigitte Wildemann, Ricarda Diem, Daniel Schwarz, Thomas Hielscher, Wolfgang Wick, Martin Bendszus, Michael O. Breckwoldt
First published July 16, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000480
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1070

Share

Article Information

vol. 5 no. 5 e480
DOI: 
https://doi.org/10.1212/NXI.0000000000000480
PubMed: 
30038948
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 30, 2018
  • Accepted in final form June 5, 2018
  • First Published July 16, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Kianush Karimian-Jazi, MD,
    2. Brigitte Wildemann, MD,
    3. Ricarda Diem, MD,
    4. Daniel Schwarz, MD,
    5. Thomas Hielscher, MSc,
    6. Wolfgang Wick, MD,
    7. Martin Bendszus, MD and
    8. Michael O. Breckwoldt, MD, PhD
  1. Kianush Karimian-Jazi, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Brigitte Wildemann, MD,
    3. Scientific Advisory Boards:

    1. Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Brigitte Wildemann has received personal fees from Biogen, Merck Serono, Novartis Pharmaceuticals, TEVA Pharma, and from Sanofi Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Brigitte Wildemann reports grants from Bundesministerium f?r Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ricarda Diem, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Daniel Schwarz, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Thomas Hielscher, MSc,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Wolfgang Wick, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial entity Hoffmann La Roche, personal payment (2) Commercial entity MSD, personal payment

    Editorial Boards:

    1. (1) Neuro Oncology, Editorial Board 2009-today (2) Neuro Oncology, Associate Editor 2013-today (3) J of Neurochemistry, Handling Editor, 2012-today (4) CNS Oncology, Associate Editor, 2012-today

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Commercial entity Prime Oncology

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Commercial entity Apogenix (2) Commercial entity Eli Lilly

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Charitable Hertie Foundation (2) German ministry of technology BMBF (3) German Research Foundation (4) German Cancer Aid

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Martin Bendszus, MD and
    8. Scientific Advisory Boards:

    1. 1. SC for ECASS 4 (non-commercial) 2. PI for TENSION(non-commercial) 3. Editorial board for Springer (commercial) 4. Adjudication committee for Boehringer (commercial) 5. Scientific advisor for BBRaun (commercial) 6. DSMB for Vascular Dynamics (commercial)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Guerbet, Bayer, Novartis, Codman, Roche, Teva

    Editorial Boards:

    1. Co-editor of "Clinical Neuroradiology"

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Research support from Novartis 2. Research support from Guerbet 3. Research support from Siemens 4. Research support from Bayer Healthcare 5. Research support from Hopp foundation 6. Research support from the European Union 7. Research support from DFG

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Hopp Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Michael O. Breckwoldt, MD, PhD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Novartis Foundation for Therapeutic Research (2) Else-Kr?ner Fresenius Stiftung (2017-A25)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neuroradiology (K.K.-J., D.S., M.B., M.O.B.), University Hospital Heidelberg, Im Neuenheimer Feld 400; Neurology Clinic (B.W., R.D., W.W.), University Hospital Heidelberg, Im Neuenheimer Feld 400; Division of Biostatistics (T.H.), German Cancer Research Center, DKFZ, Im Neuenheimer Feld 280; and Clinical Cooperation Unit Neurooncology (W.W.), German Cancer Consortium, German Cancer Research Center, DKFZ, Im Neuenheimer Feld 280, Heidelberg, Germany.
  1. Correspondence
    Dr. Breckwoldt michael.breckwoldt{at}med.uni-heidelberg.de
View Full Text

Article usage

Article usage: July 2018 to August 2023

AbstractFullPdfSource
Jul 2018021049Highwire
Aug 2018133357Highwire
Aug 201872124pmc
Sep 2018027092Highwire
Oct 2018028732Highwire
Nov 2018010117Highwire
Dec 2018011117Highwire
Jan 2019422320Highwire
Feb 201979624Highwire
Mar 2019310126Highwire
Apr 2019112711Highwire
May 2019310618Highwire
Jun 201938219Highwire
Jul 20191111818Highwire
Aug 2019412417Highwire
Sep 2019510416Highwire
Oct 20196756Highwire
Nov 201938415Highwire
Dec 201907314Highwire
Jan 20201815Highwire
Feb 202006410Highwire
Mar 202025613Highwire
Apr 202027314Highwire
May 202016920Highwire
Jun 202004811Highwire
Jul 202015410Highwire
Aug 20201368Highwire
Sep 2020716215Highwire
Oct 202047620Highwire
Nov 202053815Highwire
Dec 202045013Highwire
Jan 202123512Highwire
Feb 202122315Highwire
Mar 20217477Highwire
Apr 202155519Highwire
May 202155914Highwire
Jun 202184210Highwire
Jul 202136211Highwire
Aug 202126313Highwire
Sep 202184117Highwire
Oct 202173319Highwire
Nov 202122515Highwire
Dec 202124812Highwire
Jan 202243817Highwire
Feb 202254711Highwire
Mar 202215111Highwire
Apr 20226268Highwire
May 202244119Highwire
Jun 202244412Highwire
Jul 20222406Highwire
Aug 202272711Highwire
Sep 202253514Highwire
Oct 202238621Highwire
Nov 202287026Highwire
Dec 20222238Highwire
Jan 202344913Highwire
Feb 202344311Highwire
Mar 202353513Highwire
Apr 20236309Highwire
May 202335212Highwire
Jun 202314514Highwire
Jul 202325316Highwire
Aug 20232528Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles